Drug Overview
MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant. MOR208 has shown strong response rates in these patients in the Phase II L-MIND study, similar to those observed with chimeric antigen receptor T-cell (CAR-T) therapies, which have become a significant addition to the DLBCL treatment paradigm. MOR208 will compete with CAR-T regimens in these heavily pretreated patients and will be aided by a relatively cheap cost and improved side-effect profile. In addition, MOR208 is currently being evaluated in the Phase II/III B-MIND study (ClinicalTrials.gov identifier: NCT02763319) against the standard of care, Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo). A demonstrated survival improvement in this trial would further improve MOR208’s outlook in this indication.
Analyst Outlook
MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody (MAb) MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT). MOR208 has shown strong response rates in these patients in the Phase II L-MIND study (ClinicalTrials.gov identifier: NCT02399085), similar to those observed with chimeric antigen receptor T-cell (CAR-T) therapies, which have become a significant addition to the DLBCL treatment paradigm. MOR208 will compete with CAR-T regimens in these heavily pretreated patients and will be aided by a relatively cheap cost and improved side-effect profile. In addition, MOR208 is currently being evaluated in the Phase II/III B-MIND study (ClinicalTrials.gov identifier: NCT02763319) against the standard of care, Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo). A demonstrated survival improvement in this trial would further improve MOR208’s outlook in this indication.
MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant. MOR208 has shown strong response rates in these patients in the Phase II L-MIND study, similar to those observed with chimeric antigen receptor T-cell (CAR-T) therapies, which have become a significant addition to the DLBCL treatment paradigm. MOR208 will compete with CAR-T regimens in these heavily pretreated patients and will be aided by a relatively cheap cost and improved side-effect profile. In addition, MOR208 is currently being evaluated in the Phase II/III B-MIND study (ClinicalTrials.gov identifier: NCT02763319) against the standard of care, Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo). A demonstrated survival improvement in this trial would further improve MOR208’s outlook in this indication.
Analyst Outlook
MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody (MAb) MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT). MOR208 has shown strong response rates in these patients in the Phase II L-MIND study (ClinicalTrials.gov identifier: NCT02399085), similar to those observed with chimeric antigen receptor T-cell (CAR-T) therapies, which have become a significant addition to the DLBCL treatment paradigm. MOR208 will compete with CAR-T regimens in these heavily pretreated patients and will be aided by a relatively cheap cost and improved side-effect profile. In addition, MOR208 is currently being evaluated in the Phase II/III B-MIND study (ClinicalTrials.gov identifier: NCT02763319) against the standard of care, Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo). A demonstrated survival improvement in this trial would further improve MOR208’s outlook in this indication.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES